AIDS is a pandemic disease characterized by severe immunodeficiency in individuals infected with HIV ([@b1-idmm-25-257],[@b2-idmm-25-257]). Highly active antiretroviral therapy (HAART) is the treatment of choice for HIV-infected patients ([@b1-idmm-25-257]).

HIV-infected individuals exhibit systemic oxidative stress (OS), one of the many important biochemical alterations in the infection progression, caused by the presence of free radicals and by decreases in molecules of the antioxidant system ([@b3-idmm-25-257]). OS is further increased by HAART, which plays an important role in determining the OS in these patients, aside from affecting their metabolic status ([@b4-idmm-25-257]).

In this context, lipid peroxidation is noteworthy because its byproducts, such as thiobarbituric acid-reactive substances (TBARS), have been found in high concentrations in HIV-infected individuals ([@b5-idmm-25-257]). Lipid peroxidation can be defined as a cascade of biochemical events resulting from the action of free radicals on unsaturated fatty acids in the cell membrane, leading to the destruction of its structure; this impairs the selective permeability of the membrane, which regulates what enters and exits the cell (ie, allowing the uptake of nutrients and eliminating substances toxic to cells), thus facilitating the occurrence of intracellular damage with DNA alterations and low-density lipoprotein oxidation and, as a result, jeopardizing the integrity of extracellular matrix components ([@b6-idmm-25-257]).

Another important molecule in the oxidative processes is nitric oxide (NO), which acts as an inter- and intracellular signalling molecule in a variety of physiological and pathological functions. To date, the functions of this free radical are complex and antagonistic. It is considered to be a neurotransmitter and is also active in defending the body through antibacterial, antiparasitic and antiviral actions. In these cases, NO acts at higher concentrations than messenger concentrations and is toxic to invaders. The ability of NO to be beneficial or toxic depends on the tissue concentration and tissue clearance; the threshold of NO concentration between the toxicity required for defense action and nontoxicity to the host's cells is very small ([@b6-idmm-25-257]--[@b9-idmm-25-257]).

OS appears to play an important role in stimulating HIV replication and rapid progression of diseases with the development of immunodeficiency, which can cause cell damage and induce apoptosis, recognized as the main form of cell death of CD4+ T lymphocytes in HIV-infected individuals. This theory arose from numerous studies conducted on cell lines infected with HIV and patients infected with this virus ([@b5-idmm-25-257],[@b10-idmm-25-257]--[@b16-idmm-25-257]).

The generation of free radicals, physiological or otherwise, and their damage can be controlled by a normal endogenous antioxidant defense system, which requires an adequate intake of micronutrients with antioxidant activity (AOA) ([@b10-idmm-25-257]--[@b11-idmm-25-257],[@b17-idmm-25-257]).

Important examples of endogenous antioxidants are the enzymes superoxide dismutase, catalase and glutathione peroxidase; the nonenzymatic endogenous antioxidants such as reduced glutathione (GSH), lipoic acid, albumin, ubiquinone (coenzyme Q10), metallothioneins, transferrin and ceruloplasmin; and the (especially dietary) nonenzymatic exogenous antioxidants, such as vitamin E, vitamin C, carotenoids and flavonoids, in addition to mineral nutrients such as zinc and selenium ([@b5-idmm-25-257],[@b6-idmm-25-257]).

Randomized studies have demonstrated the benefits of micronutrient supplementation, including the reduced risk of disease progression, especially for subjects in early stages of infection. Although the role of dietary antioxidant supplementation in the treatment of individuals who are already undergoing HAART has not been defined ([@b18-idmm-25-257]), several studies have demonstrated some benefits of antioxidant supplements in HIV patients. For example, Allard et al ([@b19-idmm-25-257]) supplemented HIV-positive patients with vitamins E and C for a three-month period and found a reduction in lipid peroxidation, according to TBARS levels, compared with the control group, showing that supplementation of these vitamins reduce OS during infection. Batterham et al ([@b20-idmm-25-257]) found that antioxidant supplementation in HIV-infected individuals promoted significant improvement in some measurements of the antioxidant defense such as selenium, GSH and glutathione peroxidase. In addition, Djohan et al ([@b21-idmm-25-257]) administered antioxidant nutrients from *Alternanthera pungens* herbal tea to asymptomatic HIV-positive patients and observed a meaningful reduction in the OS marker TBARS, as well as a significant increase in the number of CD4+ and CD8+ T cells, which can prevent the onset of opportunistic diseases.

In this context, further studies are needed to elucidate the therapeutic and preventive role of micronutrients in the course of HIV infection as an adjunct to HAART ([@b12-idmm-25-257],[@b22-idmm-25-257],[@b23-idmm-25-257]).

Mushrooms in the genus *Agaricus* (*Agaricus bisporus*, *Agaricus blazei*, *Agaricus sylvaticus* and others) have been widely studied on account of their medicinal properties, such as antitumour, immune system-boosting and antibacterial properties, among others ([@b24-idmm-25-257]--[@b28-idmm-25-257]). In extracts from this mushroom, we identified many molecules that have antioxidant properties, including vitamins E and D, numerous carbohydrates, minerals and bioflavonoids; thus, there is a strong anti-oxidant potential when all of these molecules are conjugated in a single food such as in a mushroom ([@b27-idmm-25-257]). Additionally, some authors have demonstrated the benefit of the great antioxidant potential of *A sylvaticus* in malaria ([@b29-idmm-25-257],[@b30-idmm-25-257]), colorectal cancer ([@b25-idmm-25-257]) and atherosclerosis ([@b31-idmm-25-257]).

For that reason, it is of great interest to consider new treatment strategies associated with previously established antiretroviral therapy, which may slow disease progression and, thus, reduce the incidence of AIDS-related opportunistic complications, reduce mortality, increase survival and lead to a significant improvement in individuals' quality of life.

It is likely that supplementation with *A sylvaticus*, associated with HAART, may lead to reduced OS, and an improved antioxidant status and clinical condition in HIV-1 patients. Thus, the objective of the present study was to investigate the effects of supplementation containing the mushroom *A sylvaticus* on oxidative alterations and anti-oxidant defenses in children born with HIV undergoing antiretroviral therapy.

METHODS
=======

The present experimental, prospective study involved children who were selected at the Specialized Reference Unit for Maternal & Adolescent Children, a state-owned institution located in the city of Belém, Brazil, between two and eight years of age, of both sexes, who were HIV-1 positive (HIV+; n=10) and undergoing antiretroviral therapy. These subjects were compared with a second group of healthy children not infected with HIV-1 with comparable characteristics who did not receive the supplementation and formed the negative control group (HIV−, n=14; [Table 1](#t1-idmm-25-257){ref-type="table"}). All subjects in the HIV+ group were infected vertically (ie, born infected) and were taking HAART during the study period. The characteristics of HAART are presented in [Table 2](#t2-idmm-25-257){ref-type="table"}. Subjects in the HIV− group were relatives of subjects in the HIV+ group in an attempt to ensure that their life conditions were as similar as possible to those of the HIV+ subjects.

The present study included all children \<10 years of age, of both sexes, who were HIV+ and submitted to antiretroviral therapy, or HIV− children, residents of the metropolitan area of Belém (Pará, Brazil), who attended to the Specialized Reference Unit for Maternal & Adolescent Children seeking treatment or accompanying patients during the study period and whose parents and/or guardians agreed to participate by signing the consent form. Exclusion criteria included: taking any kind of supplementation of antioxidant nutrients such as multivitamins and/or polyminerals; having other associated diseases such as diabetes, hypertension and cancer; and children whose parents and/or guardians refused to participate.

Supplementation was achieved over a consecutive three-month period. To administer *A sylvaticus*, a commercially produced syrup formulation of this mushroom (Cogumelo do Sol Agaricus do Brasil LTDA, Brazil) was used, for which the formula is standardized and registered as food by the Brazil's Ministry of Health (Registration No. 6.1021.0002.001-7). The nutritional composition of this syrup is presented in [Table 3](#t3-idmm-25-257){ref-type="table"}. Each millilitre of syrup provides 300 mg of *A sylvaticus*. Dosages were adjusted according to the subjects' body weight ([Table 4](#t4-idmm-25-257){ref-type="table"}) to provide an average dose of 30 mg of mushroom per kilogram of body weight per day. Subjects were instructed to take the supplements as a single dose early in the morning with breakfast. On the same day the protocol started and before receiving the supplements, a peripheral blood sample was collected for biochemical assay (T0). Supplements were taken for 90 consecutive days and, in the morning of the following day, another blood sample was collected (T3). The procedures were conducted in a double-blinded manner, in which blood collection, laboratory testing and supplementation administration were performed by different researchers.

During the supplementation period, all subjects were instructed to avoid antioxidant supplements of any kind, and to maintain their regular food intake as usual. Daily food intake was recorded and anti-oxidant content was assessed to identify any discrepancies among individuals. If significant modification to the antioxidant content of the diet was detected, data from the subject were not included.

Sample preparation and storage
------------------------------

At the beginning (T0) and on the day immediately following the supplementation period (90 days \[T3\]), peripheral blood samples were collected for the analysis of OS and antioxidant defense markers: TBARS, nitrite and nitrate (NN) (stable metabolites of NO), Trolox equivalent antioxidant capacity (TEAC) and antioxidant capacity measured by reduction of the diphenyl-picrylhydrazyl radical (DPPH). For the subjects in HIV− group, only one blood sample was collected for laboratory testing at baseline. Samples were collected in properly identified tubes containing anticoagulant (EDTA). The tubes were centrifuged at 2500 rpm for 15 min; plasma was ready for use on being separated in a container (1.5 mL microcentrifuge tube) labelled according to the identification protocol of subjects, frozen at −20°C. The samples were thawed at room temperature for measurement and assayed in the same batch.

Laboratory evaluation of OS and antioxidant defense
---------------------------------------------------

All laboratory tests were performed in triplicates at a maximum acceptance of 5% variance. Every assay was performed with a standard curve and proper quality controls were assayed with the samples.

### TBARS:

Lipid peroxidation was determined using the TBARS assay, performed according to the method proposed by Kohn and Liversedge ([@b32-idmm-25-257]) and modified by Percário et al ([@b33-idmm-25-257]), which is based on the reaction of two molecules of thiobarbituric acid (TBA) with one molecule of malondialdehyde, at low pH (2.5) and high temperature to form TBA-malondialdehyde-TBA, a pink complex with a maximum absorption at 535 nm. The technical procedure involved the addition of 500 μL of the sample to 1.0 mL of TBA reagent (10 mM TBA dissolved in 75 mM KH~2~PO~4~). Next, the mixture was placed in a water bath (95°C) for 60 min and, after incubation, was allowed to cool at room temperature; 4.0 mL of n-butyl alcohol was then added, homogenized with a vortex mixer and centrifuged at 2500 rpm for 15 min; 3.0 mL was collected from the supernatant and absorption was measured spectrophotometrically at 535 nm (FEMTO, Brazil).

### NN:

The measurements of NN were performed using the Total NO/Nitrite/Nitrate Assay Kit (KGE001; R&D Systems, USA). NO undergoes a series of reactions with several different molecules, producing nitrate (NO~3~^−^) and nitrite (NO~2~^−^). The measurement of these products is conducted using the spectrophotometric method, with ELISA plates as support, in which the use of nitrate reductase promotes the conversion of nitrate to nitrite. Thereafter, the Griess reagent converts nitrite into a deep purple-coloured azo compound with an absorbance maximum at 540 nm. Additionally, to minimize interference produced by the Griess reagent by NADPH (cofactor of the enzyme NO synthase), a combination of small amounts of NADPH was made using a reducing catalytic system, preventing the oxidation of the NADPH to NADP^+^. The prepared plate was covered and incubated for 30 min at 37°C. On completion of the incubation period, Griess reagents I and II were added and 10 min was allowed for the colour to develop, which was followed by measurement of the absorbance at 540 nm (PerkinElmer, Victor X3).

### TEAC:

The antioxidant potential was determined according to its equivalence to a potent antioxidant known as Trolox (6-hydroxy-2,5,7,8-tetrameticromono-2-carboxylic acid; 23881-3, Aldrich Chemical Company, USA), a synthetic, water-soluble analogue of vitamin E. The method proposed by Miller et al ([@b34-idmm-25-257]), modified by Re et al ([@b35-idmm-25-257]), was followed at adapted conditions of temperature, relative proportions of reagents and measurement time. Briefly, it is a colourimetric technique based on a reaction between 2,2-azinobis-3-ethylbenzothiazoline-6-sulfonic acid diammonium (ABTS) and K~2~S~2~O~8~, directly producing radical cation ABTS+, a chromosphore of green/blue colour with maximum absorbance at 734 nm. The addition of antioxidants to this preformed radical cation reduces it, once again, to ABTS, with the extent and time scale being dependent on antioxidant capacity, concentration of the antioxidants and duration of the reaction. This can be measured using spectrophotometry to observe the change in the absorbance at 734 nm over 5 min. Thus, the extent of discolouration as an index of inhibition of the radical cation ABTS+ is determined as the total AOA of the sample, and its relationship with Trolox reactivity is subsequently calculated under the same conditions. The final results are expressed in mmol/L, corresponding to the Trolox concentration with antioxidant capacity equivalent to the analyzed sample.

### Antioxidant capacity according to DPPH radical reduction:

The antioxidant capacity was determined by reduction of the DPPH radical. The DPPH radical has a deep violet colour in solution, with strong absorption at 515 nm to 517 nm. The method proposed by Blois ([@b36-idmm-25-257]) was adapted, in which the AOA of a given substance is measured through interaction with DPPH, resulting in the irreversible formation of hydrogenated product (hydrazine), which is colourless. The AOA of the sample is expressed in terms of its ability to cause a reduction in the absorption of a DPPH solution at a given concentration. For this experiment, a solution of DPPH in 0.1 mM ethanol was prepared. In each tube, 600 mL of 0.1 mM DPPH solution in ethanol, 50 μL of sample and 350 mL of distilled water was added, to result in a final volume of 1 mL. After a period of 30 min in a water bath at 37°C, absorbance was measured at 517 nm. The initial absorbance of the DPPH solution was measured, and the changes observed in absorbance were proportional to the sample AOA. As in TEAC, a Trolox standard curve was used. The samples were deproteinized using 2 mL of trichloroacetic acid at 10% per millilitre of plasma (1:3); after homogenization in vortex, samples rested for 10 min and were centrifuged for 10 min, and the supernatant was collected. This supernatant was diluted in 0.9% NaCl (1:2). The absorbance values obtained were subtracted from the initial DPPH absorbance; concentrations were obtained from the equation of the Trolox standard curve and values were multiplied by the dilution factor of six.

Ethical aspects
---------------

The project was previously reviewed and approved by the Research Ethics Committee of the Health and Sciences Institute of the Federal University of Para (report 024/09 CEP-ICS/UFPA). Parents and/or guardians of study subjects signed written informed consent, authorizing participation in the research, in full accordance with the precepts of ethics on research with humans and with the precepts established in the Brazilian legislation ([@b37-idmm-25-257]).

Statistical analysis
--------------------

For each parameter, an analysis of possible outlier values was performed, which uses the interquartile range in the calculation (ie, the difference between the third quartile \[Q~3~\] and the first quartile \[Q~1~\]), referred to as d~j~. All values less than Q~1~ -- 3/2 d~j~ or greater than Q~3~ + 3/2 d~j~ were considered to be discrepant and were not included in the statistical calculations.

The statistical analysis was initially performed using the Kolmogorov-Smirnov normality test to verify whether the sample showed normal distribution; SPSS version 17.0 (IBM Corporation, USA) was used. Differences between initial and final values (before and after three months of supplementation) of the HIV+ group for each parameter were assessed using the paired Student's *t* test. Differences between groups (initial HIV+ versus HIV− and final HIV+ versus HIV−) were assessed using the nonpaired Student's *t* test.

To verify any possible correlation between parameters, the Pearson correlation test was performed, considering the paired values of two parameters obtained for one subject. The following meanings were considered for correlation coefficients (r): −1.00, perfect negative correlation; −0.95, strong negative correlation; −0.50, moderate negative correlation; −0.10, weak negative correlation; 0.00, no correlation; +0.10, weak positive correlation; +0.50, moderate positive correlation; +0.95, strong positive correlation; and +1.00, perfect positive correlation.

The statistical analysis was performed using BioEstat 5.0 ([@b38-idmm-25-257]). Differences were considered to be statistically significant at P\<0.05 for all tests.

RESULTS
=======

The assessed population consisted of 24 subjects, predominantly male (62.5%). Characteristics of the study population are summarized in [Table 1](#t1-idmm-25-257){ref-type="table"}.

TBARS concentrations
--------------------

The mean concentration of TBARS in the HIV+ group before supplementation was significantly higher than in the HIV− group (HIV+, 967±191 ng/mL; HIV−, 742±262 ng/mL; P=0.038). After three months, the mean value of the group supplemented with *A sylvaticus* was significantly reduced (516±168 ng/mL; 46.6% reduction, P=0.0021). [Figure 1](#f1-idmm-25-257){ref-type="fig"} shows the behaviour of TBARS before and after supplementation with *A sylvaticus*.

NN
--

The mean NN concentration in the HIV+ group before supplementation was significantly higher than in the HIV− group (HIV+, 75.2±32.7 μmol/L; HIV−, 27.4±4.83 μmol/L; P=0.0013). After three months, the mean value of the supplemented group with *A sylvaticus* was significantly reduced (48.3±10.3 μmol/L; 35.7% reduction, P=0.020). [Figure 2](#f2-idmm-25-257){ref-type="fig"} presents NN measurements before and after supplementation with *A sylvaticus*.

TEAC
----

The mean TEAC value in the HIV+ group before supplementation was not different compared with the HIV− group (HIV+, 3.43±0.13 mmol/L; HIV−, 3.44±0.10 mmol/L; P=0.786). However, after three months, the mean value of the group supplemented with *A sylvaticus* showed a significant increase (3.61±0.12 mmol/L, a 5.24% increase; P=0.0105). [Figure 3](#f3-idmm-25-257){ref-type="fig"} shows the TEAC measurements before and after supplementation with *A sylvaticus*.

Antioxidant capacity according to DPPH radical reduction
--------------------------------------------------------

The mean DPPH level in the HIV+ group before supplementation was significantly lower than in the HIV− group (HIV+, 2.76±0.12 mmol/L; HIV−, 4.42±0.20 mmol/L; P\<0.0001). After three months, the mean value of the group supplemented with *A sylvaticus* increased significantly (4.01±0.11 mmol/L; a 45.3% increase, P\<0.0001). [Figure 4](#f4-idmm-25-257){ref-type="fig"} shows the DPPH measurements before and after supplementation with *A sylvaticus*.

Correlation studies
-------------------

To better understand the behaviour of the variables assayed in the present study, correlation studies were performed. First, TBARS concentrations and TEAC values were correlated. A highly significant moderate negative correlation (r=−0.5183, P=0.0047) was observed for the HIV+ group, demonstrating that as TEAC increases, TBARS concentration decreases. In the HIV− group, there was no correlation between these variables (r=−0.0032; P=0.9914). Correlations and analyses of statistical significance are presented in [Figure 5](#f5-idmm-25-257){ref-type="fig"}.

TBARS and DPPH measurements were also correlated, a moderate negative correlation with high statistical significance (r=−0.5972, P=0.0054) in the HIV+ group, demonstrating that as DPPH values increase, TBARS concentrations decrease. In the HIV− group, there was no meaningful correlation between the variables considered (r=0.0502; P=0.8647). Correlations and their statistical significance analysis are shown in [Figure 6](#f6-idmm-25-257){ref-type="fig"}.

All correlations involving NN were not statistically significant.

DISCUSSION
==========

Before supplementation, the TBARS concentration values in the HIV+ group were observed to be significantly higher than in the HIV− group. These findings support the involvement of OS in the course of HIV infection, because it shows that this infection elevated lipid peroxidation to the highest levels in these subjects. These data are consistent with the literature, considering that studies have presented high TBARS values in infected adults ([@b14-idmm-25-257],[@b39-idmm-25-257]) and even in children ([@b40-idmm-25-257]). Additionally, after three months of supplementation with *A sylvaticus*, TBARS mean values decreased substantially, demonstrating that supplementation can reduce the OS caused by HIV infection.

When analyzing the changes in NO caused by HIV infection, the mean values in the HIV group before supplementation were significantly higher than in the HIV− group, similar to the changes observed in TBARS. Although the production of NO was intimately associated with OS observed during infection, this molecule is also considered to be an important component of the host immune response in many viral infections including retrovirus infections ([@b9-idmm-25-257],[@b41-idmm-25-257]).

Moreover, in some cases, the production of NO during infectious diseases may have deleterious effects, a fact particularly important for HIV infection, where NO may contribute to the pathogenesis of AIDS. NO production by human monocytes and macrophages may rely on the induction of expression of the enzyme NO synthase by proinflammatory cytokines, which, in turn, are induced in response to HIV infection. It has also been shown that there is a positive correlation between NO production and viral load, suggesting that HIV may induce NO synthesis in vivo, particularly in patients with neurological complications ([@b7-idmm-25-257],[@b41-idmm-25-257]).

However, existing results regarding NO performance during HIV infection are contradictory, and whether NO synthesis is a virus inhibitory factor or inducer of viral replication is not clearly established ([@b9-idmm-25-257],[@b41-idmm-25-257],[@b42-idmm-25-257]).

Similar to the TBARS values, the mean NN values showed important reduction after supplementation, suggesting that antioxidation is an inhibitory factor of NO synthesis.

The OS observed by the increased concentration of TBARS and NN resulting from HIV infection can be controlled by the antioxidant defense system. Therefore, in addition to OS markers, the antioxidant capacity of infected subjects was evaluated.

This antioxidant capacity was evaluated by its equivalence to Trolox, a potent synthetic antioxidant analogous to vitamin E. Notably, the mean values of TEAC in the HIV+ group before supplementation showed no statistically significant differences when compared with the HIV− group. However, the antioxidant capacity of subjects was also evaluated by DPPH reduction. The results obtained in the HIV+ group before supplementation were significantly lower than in the HIV− group, showing a reduced antioxidant capacity on account of HIV infection. In the literature, there are no studies evaluating the antioxidant capacity according to DPPH reduction during HIV infection, but several studies have demonstrated decreased anti-oxidant capacity in these subjects ([@b39-idmm-25-257],[@b43-idmm-25-257],[@b44-idmm-25-257]).

The reduction of total antioxidant capacity can be explained by the reduced activity of antioxidant enzymes. In later stages of the disease, glutathione peroxidase activity is low, which can be explained by the fact that its activity increases primarily after lipid peroxidation by an adaptive response similar to that of superoxide dismutase, and then is reduced as a result of consumption of its cofactors. This may lead to a worsening of the disease as opportunistic infections appear along with increased production of reactive oxygen/nitrogen species ([@b45-idmm-25-257]). However, it is noteworthy that the subjects of the present study were not in such late disease conditions; rather, they had controlled HIV/AIDS and, thus, the present study demonstrated that a decrease in antioxidant capacity in HIV+ patients can be reduced even before its latter stages.

Additionally, HIV progressively depletes GSH in humans. Despite accumulated evidence suggesting the role of reduced GSH in the pathogenesis of HIV, controversies remain about the mechanism of this depletion, especially in trying to develop appropriate therapeutic strategies to help compensate for reduced antioxidant capacity ([@b46-idmm-25-257]).

The reduction of antioxidant capacity may also be explained by the decrease of molecules such as zinc, selenium, vitamin E and carotenes, which are part of the exogenous enzymatic antioxidant system, featuring a deficiency of micronutrients markedly severe in these patients ([@b47-idmm-25-257]--[@b49-idmm-25-257]). However, it is important to note that the concentrations of these molecules were not evaluated in the present study.

According to Buys et al ([@b50-idmm-25-257]), micronutrients play a role in the pathogenesis of HIV. Children and adults infected with HIV exhibit deficiencies in several micronutrients resulting from malnutrition that accompanies the advance of the disease. These deficiencies appear to contribute to immune dysfunction, morbidity of infections and, consequently, to disease progression.

Selenium deficiency has been shown to be a significant predictor of HIV-related mortality. Despite the fact that this deficiency is relatively rare in healthy humans, a considerable number of studies have demonstrated a reduction in plasma concentrations of selenium and glutathione peroxidase activity in subjects with HIV/AIDS, which may result from the occurrence of absorptive defects in patients with the disease ([@b51-idmm-25-257]).

Additionally, HAART treatment may be responsible for part of the reduction in the antioxidant capacity of subjects as well as for the increase in oxidant molecules in those patients. In this sense, a recent study showed that, compared with control subjects, HIV-1 infected patients treated with HAART exhibited high levels of OS, in parallel with decreased levels of total AOA ([@b4-idmm-25-257]), results similar to the present findings.

In the present study, TEAC mean values increased considerably after supplementation with *A sylvaticus*. In relation to DPPH, similar behaviour was noted. Recent studies have demonstrated the beneficial effects of supplemental antioxidant nutrients in the course of HIV infection. Suttajit ([@b15-idmm-25-257]) reported that nutritional interventions may improve the nutritional status and maintain the immune system. Moreover, high doses of specific vitamins, minerals and synthetic antioxidants have been proposed to protect or reduce OS induced by reactive oxygen and nitrogen species ([@b52-idmm-25-257]--[@b54-idmm-25-257]), reflecting on the viral load ([@b19-idmm-25-257]) and on the number of CD4+ and CD8+ cells in subjects ([@b21-idmm-25-257]).

Therefore, our data combined with the data in literature suggest that nutritional intervention, such as *A sylvaticus* supplementation, can be considered an effective contribution to HIV infection treatment associated with HAART, reducing OS and improving anti-oxidant capacity in HIV patients. Nevertheless, further research is needed to better evaluate the effects of this supplementation on viral load, CD4+ and CD8+ T cell count, as well as on the quality of life of these subjects.

The authors thank Cogumelo do Sol Agaricus do Brasil Comércio, Importação e Exportação Ltda for the donation of *A sylvaticus* syrup, Nurse Carla Cepêda for technical assistance, Dr Michael Dean Green for language assistance, FAPESP and PROPESP/UFPA for providing financial support (SP) and CAPES for providing a scholarship (MSF).
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###### 

Characterization of the population studied

  **Group**   **n (%)**   **Age, years**   **Sex, n (%)**   
  ----------- ----------- ---------------- ---------------- ----------
  HIV+        10 (41.7)   3.7±2.0 ns       3 (30.0)         7 (70.0)
  HIV−        14 (58.3)   5.1±1.9          12 (85.7)        2 (14.3)
  Total       24 (100)                     15 (62.5)        9 (37.5)

*Values are expressed as mean ± SD unless otherwise indicated. HIV+ HIV-infected subjects supplemented with* Agaricus sylvaticus; *HIV− Negative controls; ns Nonsignificant versus HIV−*

###### 

Characteristics of the antiretroviral therapy administered to subjects

  **Drug**                                                 **n (%)**
  -------------------------------------------------------- -----------
  Current nucleoside reverse-transcriptase inhibitor       
    Zidovudine (azidothymidine)                            10 (100)
    Lamivudine (3TC)                                       10 (100)
    Didanosine                                             1 (10)
    Tenofovir                                              1 (10)
  Current protease inhibitor                               
    Darunavir                                              1 (10)
    Ritonavir                                              5 (50)
    Lopinavir                                              4 (40)
  Current non-nucleoside reverse-transcriptase inhibitor   
    Nevirapine                                             3 (30)
    Efavirenz                                              5 (50)
  Current integrase inhibitor                              
    Raltegravir                                            1 (10)

###### 

Nutritional information for *Agaricus sylvaticus*

  **Nutrient**              **Amount, mg/100 g**   **Nutrient**    **Amount, g/100 g**
  ------------------------- ---------------------- --------------- ---------------------
  Sodium                    4.2                    Proteins        39.4
  Iron                      21.2                   Fats            3.0
  Calcium                   35.7                   Carbohydrates   45.6
  Potassium                 3.15                   Arginine        1.71
  Magnesium                 100                    Lysine          1.55
  Copper                    8.24                   Histidine       0.62
  Zinc                      6.61                   Phenylalanine   1.11
  Manganese                 0.65                   Tyrosine        0.83
  Selenium                  0.036                  Leucine         1.72
  Thiamine (B~1~)           1.21                   Isoleucine      1.10
  Riboflavin (B~2~)         3.41                   Methionine      0.39
  Vitamin B~6~              0.83                   Valine          1.28
  Vitamin B~12~             0.00017                Alanine         1.75
  Vitamin C                 56.0                   Glycine         1.25
  Calciferol                0.0058                 Proline         1.26
  Folic acid                0.36                   Glutamic acid   5.73
  Pantothenic acid          39.4                   Serina          1.20
  Inositol                  201                    Threonine       1.21
  Niacin                    39.9                   Aspartic acid   2.35
  Phenols                   0.10                   Tryptophan      0.43
  Beta d-glucan             127                    Cistine         0.36
  Isoflavones (genistein)   0.88                                   

###### 

Dosages of mushroom *Agaricus sylvaticus* (syrup), according to body weight of subjects

  **Body weight, kg**   **Daily doses, mL**   ***A sylvaticus*, g**
  --------------------- --------------------- -----------------------
  \<10                  1                     0.30
  11--20                2                     0.60
  21--30                3                     0.90
  31--40                4                     1.20
  \>40                  5                     1.50
